CD274 and non-small cell lung carcinoma: reported that elevated PD-L1 levels are associated with EGFR mutations and EGFR TKIs treatment, suggesting that the combination of anti-PD-1/PD-L1, and EGFR TKIs might have synergistic effects in NSCLC therapy (80).